ArticleBMC medical imaging2026
Physiological distribution and dosimetry of Al
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to quantify the biodistribution of Al18F-NOTA-Pentixafor (18 F-CXCR4) using PET/CT imaging, establish reference ranges of organ radiotracer uptake, characterize uptake patterns in benign lesions, and evaluate radiation dosimetry.
methodsIn this retrospective study, we analyzed 18 F-CXCR4 PET/CT data from 51 patients, with radiotracer uptake in organs and benign lesions quantified using SUVmax and SUVmean. Biodistribution differences according to sex, age, and gallbladder excretion status were evaluated. In addition, three postmenopausal females underwent serial whole-body PET/CT imaging during the rapid distribution, equilibrium, and clearance phases of 18 F-CXCR4, and time–activity curves were used to calculate organ-absorbed doses based on the ICRP adult female model.
resultsPhysiological 18 F-CXCR4 radiotracer uptake was highest in the urinary tract, biliary system, and uterus (SUVmax ≥ 4.6), moderate in the myocardium, lungs, and pancreas (SUVmax 1.30–3.16), and lowest in the brain, spinal cord, and skeletal muscle (SUVmax ≤ 0.84). No significant sex differences were found for either SUVmax or SUVmean (P > 0.05), except for higher pancreatic SUVmean in males (P = 0.01) and higher lung and blood-pool SUVmean in females (P = 0.02). Younger patients exhibited higher biliary SUVmax than older patients (P = 0.04). Although fasted patients showed increased gallbladder tracer accumulation, the difference was not statistically significant (P = 0.06). Benign lesions demonstrated a wide range of radiotracer uptake (SUVmax 1.25–6.22). The effective dose of 18 F-CXCR4 was estimated to be 2.02E-02 mSv/MBq, with the kidneys receiving the highest absorbed dose.
conclusion18F-CXCR4 exhibits a stable physiological biodistribution profile minimally influenced by sex or age, thereby enabling the establishment of reliable diagnostic reference ranges. Analysis of CXCR4 expression in benign lesions supports basic research and diagnosis/treatment of related diseases, while confirming dosimetric safety.
trial registrationThe trial is retrospectively registered at the Chinese Clinical Trial Registry (ChiCTR) (registration number: ChiCTR2400090595, registration date: 2024–10-09).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.